NCT00084487 2014-05-23Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line ChemotherapyNational Cancer Institute (NCI)Phase 2 Terminated21 enrolled 12 charts